Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - capsule, soft - 2 microgram(s) - other anti-parathyroid agents; paricalcitol

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - capsule, soft - 1 microgram(s) - other anti-parathyroid agents; paricalcitol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - paricalcitol - oral capsule - 1microgram

United States - English - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug - zemplar capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. zemplar capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). zemplar capsules should not be given to patients with evidence of - hypercalcemia or - vitamin d toxicity [see warnings and precautions ( 5.1 )] .   risk summary limited data with zemplar capsules in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalc

United States - English - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules - paricalcitol 1 mcg - paricalcitol - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - paricalcitol - injection - 5 mcg/ml - paricalcitol 5 mcg/ml

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - fluxapyroxad - suspension concentrate - fluxapyroxad carboxamide active 300.0 g/l - fungicide

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - solution for injection - paricalcitol 5 mcg/ml - paricalcitol - paricalcitol - paricalcitol is indicated for the prevention and treatment of secondary hyperparathyrodism associated with chronic renal failure.